Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
EYPT 
Eyepoint Pharmaceuticals Inc (EYPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: EYPT (5-star) is a STRONG-BUY. BUY since 14 days. Simulated Profits (11.04%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.5
1 Year Target Price $35.5
| 9 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 381.23% | Avg. Invested days 47 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.32B USD | Price to earnings Ratio - | 1Y Target Price 35.5 |
Price to earnings Ratio - | 1Y Target Price 35.5 | ||
Volume (30-day avg) 13 | Beta 1.69 | 52 Weeks Range 3.91 - 19.11 | Updated Date 12/14/2025 |
52 Weeks Range 3.91 - 19.11 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6420.81% |
Management Effectiveness
Return on Assets (TTM) -49.39% | Return on Equity (TTM) -98.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1141046647 | Price to Sales(TTM) 31.27 |
Enterprise Value 1141046647 | Price to Sales(TTM) 31.27 | ||
Enterprise Value to Revenue 26.95 | Enterprise Value to EBITDA -11.49 | Shares Outstanding 82787220 | Shares Floating 61988587 |
Shares Outstanding 82787220 | Shares Floating 61988587 | ||
Percent Insiders 2.89 | Percent Institutions 86.68 |
About Eyepoint Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2005-01-27 | President, CEO & Director Dr. Jay S. Duker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 165 | Website https://eyepoint.bio |
Full time employees 165 | Website https://eyepoint.bio | ||
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.